ES8407473A1 - "un procedimiento para la preparacion de derivados del indol" - Google Patents

"un procedimiento para la preparacion de derivados del indol"

Info

Publication number
ES8407473A1
ES8407473A1 ES523039A ES523039A ES8407473A1 ES 8407473 A1 ES8407473 A1 ES 8407473A1 ES 523039 A ES523039 A ES 523039A ES 523039 A ES523039 A ES 523039A ES 8407473 A1 ES8407473 A1 ES 8407473A1
Authority
ES
Spain
Prior art keywords
alkyl
group
compounds
alkenyl
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES523039A
Other languages
English (en)
Other versions
ES523039A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10530876&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8407473(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ES523039A0 publication Critical patent/ES523039A0/es
Publication of ES8407473A1 publication Critical patent/ES8407473A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

PROCEDIMIENTO PARA LA OBTENCION DE DERIVADOS DE INDOL Y DE SUS SALES Y SOLVATOS, DE FORMULA (I), EN LA QUE ALQ, Y R1-R5 PUEDEN SER VARIOS RADICALES.CONSISTE EN LA REACCION DE UN COMPUESTO DE FORMULA (II), O UNA DE SUS SALES, CON UN COMPUESTO DE FORMULA HCOCH2ALQQ, O UNA DE SUS SALES O DERIVADOS PROTEGIDOS, EN LAS QUE Q PUEDE SER VARIOS RADICALES Y LOS DEMAS SIMBOLOS TIENEN EL MISMO SIGNIFICADO QUE EN LA FORMULA (I); SEGUIDA DE LA CICLIZACION DEL COMPUESTO FORMADO.ESTOS COMPUESTOS TIENEN APLICACIONES FARMACOLOGICAS PARA EL TRATAMIENTO DE LA JAQUECA.
ES523039A 1982-06-07 1983-06-07 "un procedimiento para la preparacion de derivados del indol" Expired ES8407473A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8216526 1982-06-07

Publications (2)

Publication Number Publication Date
ES523039A0 ES523039A0 (es) 1984-10-01
ES8407473A1 true ES8407473A1 (es) 1984-10-01

Family

ID=10530876

Family Applications (3)

Application Number Title Priority Date Filing Date
ES523039A Expired ES8407473A1 (es) 1982-06-07 1983-06-07 "un procedimiento para la preparacion de derivados del indol"
ES529802A Expired ES8601880A1 (es) 1982-06-07 1984-02-16 Un procedimiento para la preparacion de derivados del indol
ES544281A Expired ES8609247A1 (es) 1982-06-07 1985-06-17 Un procedimiento para la preparacion de derivados del indol

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES529802A Expired ES8601880A1 (es) 1982-06-07 1984-02-16 Un procedimiento para la preparacion de derivados del indol
ES544281A Expired ES8609247A1 (es) 1982-06-07 1985-06-17 Un procedimiento para la preparacion de derivados del indol

Country Status (33)

Country Link
US (1) US4816470A (es)
JP (1) JPS5942366A (es)
KR (1) KR900006681B1 (es)
AT (1) AT381933B (es)
AU (1) AU566149B2 (es)
BE (1) BE896986A (es)
CA (1) CA1199643A (es)
CH (1) CH657359A5 (es)
CY (1) CY1458A (es)
CZ (1) CZ280529B6 (es)
DE (2) DE19375045I2 (es)
DK (1) DK260183D0 (es)
DO (1) DOP1989476000A (es)
ES (3) ES8407473A1 (es)
FI (1) FI79530C (es)
FR (1) FR2530625B1 (es)
GB (1) GB2124210B (es)
GR (1) GR79215B (es)
HK (1) HK14789A (es)
IE (1) IE55358B1 (es)
IL (1) IL68913A (es)
IT (1) IT1170387B (es)
KE (1) KE3833A (es)
LU (1) LU84852A1 (es)
MX (1) MX9202623A (es)
MY (1) MY8700179A (es)
NL (1) NL193694C (es)
NZ (1) NZ204482A (es)
PH (1) PH19908A (es)
PT (1) PT76830B (es)
SE (1) SE452459B (es)
SK (1) SK404091A3 (es)
ZA (1) ZA834110B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2055651A1 (es) * 1992-07-20 1994-08-16 Vita Invest Sa Procedimiento para la obtencion de nuevas amidinas derivadas de 3-aminoetilindoles.

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU196752B (en) * 1983-12-06 1989-01-30 Glaxo Group Ltd Process for production of medical compositions containing indole-derivatives and these compounds
GB8332434D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Production of chemical compounds
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
GB8419575D0 (en) * 1984-08-01 1984-09-05 Glaxo Group Ltd Chemical compounds
US5270333A (en) * 1986-01-28 1993-12-14 Glaxo Group Limited Indole derivatives
GB8601959D0 (en) * 1986-01-28 1986-03-05 Glaxo Group Ltd Indole derivatives
GB8615599D0 (en) * 1986-06-26 1986-07-30 Glaxo Group Ltd Chemical compounds
US4997841A (en) * 1987-08-13 1991-03-05 Glaxo Group Limited Indole derivatives
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
US5225431A (en) * 1987-10-23 1993-07-06 Burroughs Wellcome Co. Therapeutic substituted indole compounds and compositions thereof
GB8903036D0 (en) * 1989-02-10 1989-03-30 Glaxo Group Ltd Chemical compounds
HUT57185A (en) * 1990-03-21 1991-11-28 Merrell Dow Pharma Process for producing 8-sulfamil-methylen-2-amino-tetraline derivatives and pharmaceutical compositions containing them
US5935925A (en) * 1990-05-08 1999-08-10 Synaptic Pharmaceutical Corporation Methods of treating migraine and compounds useful for such methods
US5155218A (en) 1990-05-08 1992-10-13 Neurogenetic Corporation Dna encoding human 5-ht1d receptors
AU646871B2 (en) * 1990-06-07 1994-03-10 Astrazeneca Uk Limited Therapeutic heterocyclic compounds
GB9013845D0 (en) * 1990-06-21 1990-08-15 Glaxo Group Ltd Process
CA2043709C (en) * 1990-06-29 2002-01-22 David W. Smith Antimigraine alkoxypyrimidine derivatives
US5077293A (en) * 1990-06-29 1991-12-31 Bristol-Myers Squibb Co. 1-indolyalkyl-4-(alkoxypyrimidinyl)piperazines
GB9022250D0 (en) * 1990-10-12 1990-11-28 Glaxo Group Ltd Medicaments
GB9103770D0 (en) * 1991-02-22 1991-04-10 Glaxo Group Ltd Chemical compounds
GB9104890D0 (en) 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
CA2084531A1 (en) 1991-12-19 1993-06-20 David W. Smith Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
GB9209882D0 (en) * 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9211276D0 (en) * 1992-05-28 1992-07-15 Glaxo Lab Sa Pharmaceutical compositions
GB9216009D0 (en) * 1992-07-28 1992-09-09 Almirall Lab New indol derivatives
ES2056025B1 (es) * 1992-10-08 1995-05-01 Almirall Lab Nuevos derivados de indol.
US5382592A (en) * 1993-09-16 1995-01-17 Bristol-Myers Squibb Company Antimigraine cyclobutenedione derivatives of tryptamines
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
ES2079323B1 (es) * 1994-06-21 1996-10-16 Vita Invest Sa Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes.
FR2731224B1 (fr) * 1995-03-02 1997-05-30 Pf Medicament Nouveaux derives bi-tryptaminiques sulfonamides, leur procede de preparation et leur utilisation a titre de medicaments
US5618816A (en) * 1995-03-02 1997-04-08 Bristol-Myers Squibb Company Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridnyl and pyrimidinylpiperazines
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6416472B1 (en) 1997-11-06 2002-07-09 Edus Inc. Method and device for measuring cognitive efficiency
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
GB9926250D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Chemical process
AU2001285156A1 (en) * 2000-08-23 2002-03-04 Bristol-Myers Squibb Company Combination therapy for the treatment of migraine
CN1536986B (zh) * 2001-03-27 2012-07-04 沃纳奇尔科特(爱尔兰)有限公司 用于抗微生物剂给药的阴道内药物递送装置
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
DE60228294D1 (en) * 2001-06-05 2008-09-25 Ronald Aung-Din Topische migränetherapie
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
AU2003243605A1 (en) * 2002-06-13 2003-12-31 Dr. Reddy's Laboratories Limited 3-'2-(dimethylamino) ethyl!-n-methyl-1h-indole-5-methanesulfonamide and the succinate thereof
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
CA2508290C (en) 2002-12-20 2017-02-28 Ciba Specialty Chemicals Holding Inc. Synthesis of amines and intermediates for the synthesis thereof
US7332183B2 (en) 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
WO2004110492A2 (en) * 2003-06-06 2004-12-23 Glaxo Group Limited Composition comprising triptans and nsaids
CA2529528A1 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
CA2540059C (en) * 2003-09-26 2013-08-06 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
ATE504288T1 (de) * 2003-09-26 2011-04-15 Alza Corp Oros-push-stick für die kontrollierte abgabe von wirkstoffen
ATE544447T1 (de) * 2003-09-26 2012-02-15 Alza Corp Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
AU2004275816A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
CA2569964A1 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US7375219B2 (en) 2005-04-13 2008-05-20 Neuraxon, Inc. Substituted indole compounds having NOS inhibitory activity
WO2007070504A2 (en) * 2005-12-13 2007-06-21 Morton Grove Pharmaceuticals, Inc. Stable and palatable oral liquid sumatriptan compositions
AR060451A1 (es) * 2006-04-13 2008-06-18 Neuraxon Inc Compuestos de indol 1,5 y 3,6-sustituidos con actividad inhibitoria de nos
ATE502921T1 (de) * 2006-10-19 2011-04-15 Auspex Pharmaceuticals Inc Substituierte indole
US20090131503A1 (en) * 2007-11-16 2009-05-21 Annedi Subhash C 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
CA2705422A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
EA201000808A1 (ru) * 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
US8580791B2 (en) 2008-05-27 2013-11-12 Biota Scientific Management Pty Ltd Antiviral 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole bis-dihydrogen-phosphate salts
WO2009152551A1 (en) * 2008-06-20 2009-12-23 Alphapharm Pty Ltd Pharmaceutical formulation
WO2010005507A1 (en) * 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
AU2010299607B2 (en) 2009-09-25 2016-07-28 Tonix Medicines, Inc. Formulations comprising triptan compounds
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
CN107530318A (zh) 2015-03-02 2018-01-02 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US10537554B2 (en) 2015-08-05 2020-01-21 Upsher-Smith Laboratories, Llc Pharmaceutical composition for treating migraine
AU2017211684B2 (en) 2016-01-27 2022-10-06 Instar Technologies A.S. Oromucosal nanofiber carriers for therapeutic treatment
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
NL8103764A (nl) * 1980-08-12 1982-03-01 Glaxo Group Ltd Heterocyclische verbindingen, werkwijze ter bereiding daarvan, alsmede farmaceutische preparaten die deze verbindingen als actieve component bevatten.
CH651551A5 (fr) * 1980-08-12 1985-09-30 Glaxo Group Ltd Derives de l'indole, leur preparation et compositions pharmaceutiques les contenant.
GB2082175B (en) * 1980-08-12 1984-05-02 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2055651A1 (es) * 1992-07-20 1994-08-16 Vita Invest Sa Procedimiento para la obtencion de nuevas amidinas derivadas de 3-aminoetilindoles.

Also Published As

Publication number Publication date
IE831335L (en) 1983-12-07
CA1199643A (en) 1986-01-21
ATA208483A (de) 1986-05-15
IL68913A (en) 1987-08-31
FR2530625B1 (fr) 1986-04-18
AU1544183A (en) 1983-12-15
CZ280529B6 (cs) 1996-02-14
GB2124210B (en) 1985-11-13
ES544281A0 (es) 1986-07-16
JPH0329069B2 (es) 1991-04-23
FI79530C (fi) 1990-01-10
CY1458A (en) 1989-07-21
IE55358B1 (en) 1990-08-29
CZ404091A3 (en) 1993-04-14
JPS5942366A (ja) 1984-03-08
PT76830B (en) 1986-04-21
KR900006681B1 (ko) 1990-09-17
PT76830A (en) 1983-07-01
HK14789A (en) 1989-02-24
IL68913A0 (en) 1983-10-31
DK260183D0 (da) 1983-06-06
KR840005095A (ko) 1984-11-03
NZ204482A (en) 1986-09-10
FI79530B (fi) 1989-09-29
US4816470A (en) 1989-03-28
ZA834110B (en) 1985-01-30
SE8303208D0 (sv) 1983-06-07
GB2124210A (en) 1984-02-15
FR2530625A1 (fr) 1984-01-27
AT381933B (de) 1986-12-10
BE896986A (fr) 1983-12-07
MX9202623A (es) 1992-06-30
FI832035A0 (fi) 1983-06-07
SK277877B6 (en) 1995-06-07
DOP1989476000A (es) 1996-02-03
NL193694B (nl) 2000-03-01
DE3320521A1 (de) 1983-12-08
DE3320521C2 (es) 1992-06-25
SE452459B (sv) 1987-11-30
LU84852A1 (fr) 1985-03-29
SE8303208L (sv) 1983-12-08
GB8315564D0 (en) 1983-07-13
ES8609247A1 (es) 1986-07-16
MY8700179A (en) 1987-12-31
SK404091A3 (en) 1995-06-07
ES523039A0 (es) 1984-10-01
CH657359A5 (fr) 1986-08-29
FI832035L (fi) 1983-12-08
DE19375045I2 (de) 2002-09-05
PH19908A (en) 1986-08-13
NL193694C (nl) 2000-07-04
IT1170387B (it) 1987-06-03
ES529802A0 (es) 1985-11-16
KE3833A (en) 1988-11-18
GR79215B (es) 1984-10-22
NL8302031A (nl) 1984-01-02
IT8348422A0 (it) 1983-06-03
ES8601880A1 (es) 1985-11-16
AU566149B2 (en) 1987-10-08

Similar Documents

Publication Publication Date Title
ES8609247A1 (es) Un procedimiento para la preparacion de derivados del indol
ES8800150A1 (es) Un procedimiento para la preparacion de derivados de indol
DE3167757D1 (en) Dibenz(b,f)(1,4)oxazepine derivatives, process for preparing the same, and pharmaceutical compositions comprising the same
DE3363244D1 (en) Compounds, process for their preparation and their use as pharmaceutical preparations
ES2001936A6 (es) Procedimiento para la preparacion de indoles sustituidos con heterociclos.
IE811830L (en) Indoles.
IL79841A (en) 2,3-dihydro-1,3,4-thiadiazole 2-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
ES8503339A1 (es) Procedimiento para la obtencion de tetrahidropiridazinonas
SE8505715L (sv) Indolderivat
DE3160360D1 (en) 5-subsituted 5,10-dihydro-11h-dibenzo(b,e)(1,4)diazepin-11-ones, process for preparing them and medicaments containing them
PT75602A (fr) Procede de preparation de nouvelles triazoloquinazolones et de leurs sels
PL243950A1 (en) Process for preparing derivatives of phenylcyclobutylamine
ES8203867A1 (es) Procedimiento para la obtencion de derivados de benzotiazol
ATE37368T1 (de) Benzothiazolon-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
DE3373302D1 (en) Derivatives of aminopyridinecarboxylic acids, methods for their preparation and pharmaceutical compositions containing them
HUT44500A (en) Process for producing methionin-substituted new 1,4-dihydro-pyridine derivatives and pharmaceutical compositions containing them
ES8704459A1 (es) Procedimiento para la obtencion de acemetacina.
YU246482A (en) Process for preparing 1-furyl-3,4-dihydro-isoquinolines
HUT44502A (en) Process for producing 3-amino-dihydropyridine derivatives and pharmaceutical compositions containing them
EG16489A (en) Process for the preparation of accridanone derivatives
ZA838139B (en) Semicarbazides,process for preparing these,and pharmaceutical compositions thereof
DK214190A (da) 5-aminosulfonylmethyl-indolderivater og farmaceutiske praeparater med indhold deraf